Navigation Links
Medivation Announces Upcoming Scientific Presentations at Medical Conferences
Date:4/23/2009

SAN FRANCISCO, April 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced several presentations at upcoming medical conferences that will feature its investigational drugs MDV3100 and Dimebon.

MDV3100

2009 American Urological Association (AUA) Annual Meeting, April 25-30, Chicago

  • Podium presentation featuring MDV3100 on Sunday, April 26, at 4:00 p.m. Central Time (POD17. Prostate Cancer: Advanced

Dimebon

61st American Academy of Neurology (AAN) Annual Meeting, April 25 - May 2, Seattle

  • Two poster presentations featuring Dimebon that will take place on:
    • Wednesday, April 29, at 4:00 p.m. Pacific Time (Poster Session VI)
    • Thursday, April 30, at 11:30 a.m. Pacific Time (Poster Session VIII)

About MDV3100

MDV3100 is a novel small-molecule androgen receptor antagonist drug candidate in development for the treatment of castration-resistant (also known as hormone-refractory) prostate cancer (CRPC). MDV3100 has completed enrollment in a Phase 1-2 study and is expected to enter Phase 3 development this year in patients with CRPC who have failed docetaxel-based chemotherapy.

MDV3100 has a novel mechanism of action unlike that of the leading anti-androgen therapy used to treat CRPC. This mechanism potentially explains why MDV3100 has demonstrated beneficial effects in patients whose tumors are no longer responding to the currently available treatments for prostate cancer, including bicalutamide.

About Dimebon

Dimebon is an investigational compound currently in Phase 3 develop
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Senior Management Promotions
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
8. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
11. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... mathematician (1912-1954), is famous for a number of breakthroughs, ... 1936 he published a paper, which laid the foundation ... a computer algorithm. He next played a pivotal role ... cracked the German military codes, enabling the Allies to ... the late 1940,s he turned his attention to artificial ...
(Date:7/31/2014)... 2014 According to a new ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 88.5 million in 2011, which is expected ... a CAGR of 53.8% from 2013 to 2023. ... http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand for energy efficient ...
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
(Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Morria Biopharmaceuticals,Plc, a biopharmaceutical company focused on ... ICH compliant Phase II equivalent,multi-center study of MRX-4 ... given as an intranasal spray formulation., The ... allergic,rhinitis patients outside of the local allergy season. ...
... new apoA1 measurement and apoB:apoA1 ratio to its, comprehensive cholesterol ... ... heart disease, BIRMINGHAM, Ala., Nov. 6 Atherotech, ... Test in booth No. 2918 at the American Heart Association,Scientific Sessions ...
... 6 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) ... 30, 2008, the first quarter of the,company,s fiscal year ... September 30, 2008 was $3.6 million, compared to $3.9 ... expenses were $6.8 million,for the first quarter of fiscal ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 3Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 4Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 5
(Date:7/30/2014)... reversible epigenetic processes to regulate its genes, and adapt ... picture of the genome regulation taking place in the ... Genome Biology and illustrates how the truffle deals ... The authors say this may shed light on how ... truffles (Tuber melanosporum), also known as Prigord truffles, have ...
(Date:7/30/2014)... the potential effects of climate change on the ... the wrong factors, according to a new paper ... Society, University of Queensland, and other organizations. The ... is missing the point when it comes to ... climate change scientists focus on the "direct" threats ...
(Date:7/30/2014)... a joint venture between The University of Texas at ... Science Center at San Antonio, has selected the winners ... Boice from UTSA and Lei Huang from the Health ... "Novel engineered ferritins for tracking and protecting neural stem ... is focused on finding a treatment for stroke through ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... The Missouri Botanical Garden in St. Louis, Mo. ... of China,s botanical institutions in an effort to promote ... beneficial agreement between the Missouri Botanical Garden and the ... of Botany calls for the exchange of herbarium specimens, ...
... the University of Georgia have developed a "super strain" ... pine -- one of the most common species of ... help biofuels replace gasoline as a transportation fuel. ... such as pine, but it is a notoriously difficult ...
... GAITHERSBERG, MD, Nov. 18 As clinical studies ... promote general gastrointestinal health, a growing U.S. market1 for ... alike are recognizing the value of these beneficial microorganisms. ... directing patients to the best probiotic for their individual ...
Cached Biology News:Missouri Botanical Garden signs exchange agreement with 3 botanical institutions in China 2UGA researchers develop 'super' yeast that turns pine into ethanol 2As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 2As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 3
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
Biology Products: